Synlab, a leading European company for human and veterinary laboratory services, has just taken the fork in the road with a volume of €772 million and is planning an IPO.
The Munich-based company, which offered environmental analyses in addition to these services and was formed from a merger of the two laboratory service providers Labco and Synlab, has also just set the final unit price per share at 18 euros, although this had been the lower end of the targeted price range of up to 23 euros. All shareholders, including financial investors, must also accept that only 20.7 million shares will be issued. The target had been 27.5 million. Share certificates for 22.2 million euros will be added from a capital increase, and proceeds of 400 million euros generated by Europe’s largest laboratory chain will also be used to repay debts.
The successful company, which is judged on sales and tests performed, currently employs 20,000 people, mainly providing clinical laboratory services and offering medical diagnostics. The company is experiencing a real upswing at the moment, partly because laboratories are evaluating PCR tests for analysis for coronavirus variants en masse.
Source: www.aerzteblatt.de